LONDON – A study from Oxford University found that the number of people who get blood clots after being vaccinated with a coronavirus vaccine is about the same for those receiving Pfizer and Moderna as for those being vaccinated with AstraZeneca.
According to the study, 4 out of 1 million people suffer from cerebral venous thrombosis (CVD) after receiving the Pfizer or Moderna vaccine, compared to 5 out of 1 million people with the AstraZeneca vaccine.
The risk of contracting CVD is much higher for those who get Covid-19 (39 out of a million patients) than for those who get vaccinated.
The use of the AstraZeneca vaccine has been stopped or restricted in many countries due to blood clot problems.
The risk of cerebral vein thrombosis, which has led many regulators to discontinue or discontinue the use of AstraZeneca and J&J vaccines, appears to be very similar for the AstraZeneca vaccine (5 in 1 million) as for the Pfizer and Moderna mRNA vaccines (4 out of a million). pic.twitter.com/KZcMCIQVXd
– Sputnik V (@sputnikvaccine)
April 16, 2021
The disaggregated comparison of CVD cases reported in patients with Covid-19 compared to CCT cases in those who received a Covid-19 vaccine is:
In this study of more than 500,000 patients with Covid-19, TVC appeared in 39 of every million patients.
In more than 480,000 people who received an mRNA vaccine against Covid-19 (Pfizer or Moderna), TVC appeared in 4 out of a million.
CVD has been reported in approximately 5 out of every 1 million people after the first dose of AstraZeneca vaccine.
Compared to mRNA vaccines, the risk of a Covid-19 CVT is about 10 times higher.
Compared to the AstraZeneca vaccine, the risk of a Covid-19 CVT is about 8 times higher.
However, they requested that all comparisons be interpreted with caution, as the data are still being analyzed.
In conclusion:
The risk of CVD after the first dose of AstraZeneca is 5 in every million people vaccinated; that of having a cerebral venous thrombosis after a Pfizer or Moderna vaccine is 4 out of every million; that of suffering from this rare thrombus in patients with covid, 39 out of every million. For the study, 513,284 patients infected with coronavirus and 489,871 with a messenger RNA vaccine (Pfizer or Moderna) were considered. The risk data for AstraZeneca are as described by the EMA.